晚期结直肠癌的当前伴随诊断；分得更大更好的份额。
Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie.
作者信息
Loree Jonathan M, Kopetz Scott, Raghav Kanwal P S
机构信息
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
出版信息
J Gastrointest Oncol. 2017 Feb;8(1):199-212. doi: 10.21037/jgo.2017.01.01.
Abstract
While the treatment of colorectal cancer continues to rely heavily on conventional cytotoxic therapy, an increasing number of targeted agents are under development. Many of these treatments require companion diagnostic tests in order to define an appropriate population that will derive benefit. In addition, a growing number of biomarkers provide prognostic information about a patient's malignancy. As we learn more about these biomarkers and their assays, selecting the appropriate companion diagnostic becomes increasingly important. In the case of many biomarkers, there are numerous assays which could provide the same information to a treating physician, however each assay has strengths and weaknesses. Institutions must balance cost, assay sensitivity, turn-around time, and labor resources when selecting which assay to offer. In this review we will discuss the current state of companion diagnostics available in metastatic colorectal cancer and explore emerging biomarkers and their assays. We will focus on and testing, as well as microsatellite stability assessment and multigene panels.
摘要
虽然结直肠癌的治疗仍严重依赖传统的细胞毒性疗法，但越来越多的靶向药物正在研发中。这些治疗方法中的许多都需要配套诊断测试，以便确定能从中获益的合适人群。此外，越来越多的生物标志物可提供有关患者恶性肿瘤的预后信息。随着我们对这些生物标志物及其检测方法的了解越来越多，选择合适的配套诊断变得越来越重要。对于许多生物标志物而言，有众多检测方法可为治疗医生提供相同的信息，然而每种检测方法都有优缺点。机构在选择提供哪种检测方法时，必须在成本、检测灵敏度、周转时间和人力资源之间取得平衡。在本综述中，我们将讨论转移性结直肠癌中现有配套诊断的现状，并探索新兴的生物标志物及其检测方法。我们将重点关注 和 检测，以及微卫星稳定性评估和多基因检测板。
相似文献
1
Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie.晚期结直肠癌的当前伴随诊断；分得更大更好的份额。
J Gastrointest Oncol. 2017 Feb;8(1):199-212. doi: 10.21037/jgo.2017.01.01.
2
Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.结直肠癌患者综合治疗中的预测和预后因素。
Magy Onkol. 2010 Dec;54(4):383-94. doi: 10.1556/MOnkol.54.2010.4.13.
3
A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.2015年预测性分子病理学及其在靶向癌症治疗中的作用更新：聚焦临床相关性的综述
Cancer Gene Ther. 2015 Sep;22(9):417-30. doi: 10.1038/cgt.2015.39. Epub 2015 Sep 11.
4
Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics.穿越激流：基于新一代测序的临床试验检测方法及伴随诊断的发展历程
Front Oncol. 2014 Apr 17;4:78. doi: 10.3389/fonc.2014.00078. eCollection 2014.
5
How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review.我们如何评估靶向癌症治疗的伴随生物标志物的成本效益？系统评价。
BMC Cancer. 2021 Sep 1;21(1):980. doi: 10.1186/s12885-021-08725-4.
6
Analytical Performance of a Highly Sensitive System to Detect Gene Variants Using Next-Generation Sequencing for Lung Cancer Companion Diagnostics.用于肺癌伴随诊断的高灵敏度系统利用下一代测序检测基因变异的分析性能
Diagnostics (Basel). 2023 Apr 19;13(8):1476. doi: 10.3390/diagnostics13081476.
7
BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.BRAF、PIK3CA和HER2致癌性改变与晚期结直肠癌远处转移的KRAS突变状态的关系
PLoS One. 2016 Mar 18;11(3):e0151865. doi: 10.1371/journal.pone.0151865. eCollection 2016.
8
Comparison of Next-Generation Sequencing and Polymerase Chain Reaction for Personalized Treatment-Related Genomic Status in Patients with Metastatic Colorectal Cancer.下一代测序与聚合酶链反应在转移性结直肠癌患者个性化治疗相关基因组状态评估中的比较
Curr Issues Mol Biol. 2022 Apr 5;44(4):1552-1563. doi: 10.3390/cimb44040106.
9
Biomarker-directed Targeted Therapy in Colorectal Cancer.生物标志物导向的结直肠癌靶向治疗
J Dig Cancer Rep. 2015 Jun;3(1):5-10.
10
Development, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital.通过下一代测序进行分子诊断在癌症个性化治疗中的开发、实施与评估：一家公立参考医疗医院的经验
Cancers (Basel). 2019 Aug 16;11(8):1196. doi: 10.3390/cancers11081196.
引用本文的文献
1
Induced clustering of SHP2-depleted tumor cells in vascular islands restores sensitivity to MEK/ERK inhibition.在血管岛中诱导SHP2缺失的肿瘤细胞聚集可恢复对MEK/ERK抑制的敏感性。
J Clin Invest. 2025 Mar 25;135(10). doi: 10.1172/JCI181609. eCollection 2025 May 15.
2
Efficacy and safety of trifluridine/tipiracil plus bevacizumab across different subgroups of patients with refractory colorectal cancer: a meta-analysis.曲氟尿苷/替匹嘧啶联合贝伐单抗治疗难治性结直肠癌不同亚组患者的疗效与安全性：一项荟萃分析
Ecancermedicalscience. 2024 Jul 10;18:1728. doi: 10.3332/ecancer.2024.1728. eCollection 2024.
3
Early Detection, Precision Treatment, Recurrence Monitoring: Liquid Biopsy Transforms Colorectal Cancer Therapy.早期检测、精准治疗、复发监测：液体活检改变结直肠癌治疗方式
Curr Cancer Drug Targets. 2025;25(6):586-619. doi: 10.2174/0115680096295070240318075023.
4
Platform combining statistical modeling and patient-derived organoids to facilitate personalized treatment of colorectal carcinoma.结合统计建模和患者来源的类器官的平台，以促进结直肠癌的个体化治疗。
J Exp Clin Cancer Res. 2023 Apr 3;42(1):79. doi: 10.1186/s13046-023-02650-z.
5
Emerging Role of ERBB2 in Targeted Therapy for Metastatic Colorectal Cancer: Signaling Pathways to Therapeutic Strategies.ERBB2在转移性结直肠癌靶向治疗中的新兴作用：从信号通路到治疗策略
Cancers (Basel). 2022 Oct 21;14(20):5160. doi: 10.3390/cancers14205160.
6
Cationic copolymers that enhance wild-type-specific suppression in BNA-clamp PCR and preferentially increase the of fully matched complementary DNA and BNA strands.阳离子共聚物，可增强BNA夹式PCR中野生型特异性抑制作用，并优先增加完全匹配的互补DNA和BNA链的 （此处原文似乎不完整，缺少具体所增加的内容） 。
Biol Methods Protoc. 2022 Mar 30;7(1):bpac009. doi: 10.1093/biomethods/bpac009. eCollection 2022.
7
Screening of important metabolites and KRAS genotypes in colon cancer using secondary ion mass spectrometry.使用二次离子质谱法筛选结肠癌中的重要代谢物和KRAS基因型。
Bioeng Transl Med. 2020 Nov 17;6(2):e10200. doi: 10.1002/btm2.10200. eCollection 2021 May.
8
Novel CRISPR-based sequence specific enrichment methods for target loci and single base mutations.基于新型 CRISPR 的靶基因和单碱基突变序列特异性富集方法。
PLoS One. 2020 Dec 23;15(12):e0243781. doi: 10.1371/journal.pone.0243781. eCollection 2020.
9
Expanded Low Allele Frequency and V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial.转移性结直肠癌中低等位基因频率和 V600E 检测作为 CO.17 试验中 Cetuximab 的预测生物标志物的扩展研究。
Clin Cancer Res. 2021 Jan 1;27(1):52-59. doi: 10.1158/1078-0432.CCR-20-2710. Epub 2020 Oct 21.
10
Population-based Screening for in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis.基于人群的转移性结直肠癌筛查揭示了更高的患病率和较差的预后。
Clin Cancer Res. 2020 Sep 1;26(17):4599-4605. doi: 10.1158/1078-0432.CCR-20-1024. Epub 2020 Jun 22.
本文引用的文献
1
Validation of Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer.扩增作为转移性结直肠癌抗表皮生长因子受体抗体治疗预测生物标志物的验证
JCO Precis Oncol. 2019 Dec;3:1-13. doi: 10.1200/PO.18.00226.
2
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.基于分子谱的晚期实体瘤的靶向治疗：MyPathway 研究的结果，一项开放标签、Ⅱa 期多篮子研究。
J Clin Oncol. 2018 Feb 20;36(6):536-542. doi: 10.1200/JCO.2017.75.3780. Epub 2018 Jan 10.
3
Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis.肿瘤PIK3CA突变在结直肠癌中的预后作用：一项系统评价和荟萃分析。
Ann Oncol. 2016 Oct;27(10):1836-48. doi: 10.1093/annonc/mdw264. Epub 2016 Jul 19.
4
Highly sensitive detection of the PIK3CA (H1047R) mutation in colorectal cancer using a novel PCR-RFLP method.使用新型PCR-RFLP方法对结直肠癌中PIK3CA（H1047R）突变进行高灵敏度检测。
BMC Cancer. 2016 Jul 12;16:454. doi: 10.1186/s12885-016-2493-9.
5
Clinical Next-Generation Sequencing Pipeline Outperforms a Combined Approach Using Sanger Sequencing and Multiplex Ligation-Dependent Probe Amplification in Targeted Gene Panel Analysis.在靶向基因panel分析中，临床下一代测序流程优于使用桑格测序和多重连接依赖探针扩增的联合方法。
J Mol Diagn. 2016 Sep;18(5):657-667. doi: 10.1016/j.jmoldx.2016.04.002. Epub 2016 Jul 2.
6
Treating Tumors by Molecular Profile, Not Type.根据分子特征而非类型治疗肿瘤。
Cancer Discov. 2016 Jul;6(7):688. doi: 10.1158/2159-8290.CD-NB2016-069. Epub 2016 Jun 8.
7
BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features.转移性结直肠癌中的BRAF V600E突变：检测方法及其与临床和病理特征的相关性
Cancer Biol Ther. 2016 Aug 2;17(8):840-8. doi: 10.1080/15384047.2016.1195048.
8
Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas.p16和BRAFV600E的免疫组织化学染色有助于鉴别散发性和遗传性（林奇综合征相关）微卫星不稳定型结直肠癌。
Virchows Arch. 2016 Aug;469(2):135-44. doi: 10.1007/s00428-016-1958-1. Epub 2016 May 25.
9
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.曲妥珠单抗联合拉帕替尼治疗经治、KRAS 密码子 12/13 野生型、HER2 阳性转移性结直肠癌（HERACLES）：一项概念验证、多中心、开放标签、Ⅱ期临床试验。
Lancet Oncol. 2016 Jun;17(6):738-746. doi: 10.1016/S1470-2045(16)00150-9. Epub 2016 Apr 20.
10
Clinicopathological significance and diagnostic accuracy of HER2 immunohistochemistry in colorectal cancer: a meta-analysis.人表皮生长因子受体2免疫组化在结直肠癌中的临床病理意义及诊断准确性：一项荟萃分析
Int J Biol Markers. 2016 Dec 23;31(4):e389-e394. doi: 10.5301/jbm.5000208.
Zotero 插件